Pfizer Invests $43 Billion to Battle Cancer

< Back to all news

Pfizer Invests $43 Billion to Battle Cancer


Category: Business News

NEW YORK & BOTHELL, Wash.–(BUSINESS WIRE)– Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction.

Read full article.

Source: Pfizer